drugset / Trial / NCT00768040

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040

Phase 2 Terminated 39 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema

Timeline

Start
2008-09
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg Oral